{"id":169910,"date":"2023-08-17T21:32:14","date_gmt":"2023-08-18T02:32:14","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/08\/next-generation-cancer-therapy-reveals-major-opportunity"},"modified":"2023-08-17T21:32:14","modified_gmt":"2023-08-18T02:32:14","slug":"next-generation-cancer-therapy-reveals-major-opportunity","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/08\/next-generation-cancer-therapy-reveals-major-opportunity","title":{"rendered":"Next Generation Cancer Therapy Reveals Major Opportunity"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/next-generation-cancer-therapy-reveals-major-opportunity2.jpg\"><\/a><\/p>\n<p>GTB-3550 is the company\u2019s first TriKE\u00ae product candidate that was evaluated in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies. Phase 1 clinical trials were shown to be both safe and well-tolerated, as well as proving the molecule\u2019s clinical concept and providing a framework for future product candidates.<\/p>\n<p>GTB-3650 is a second-generation protein developed to treat AML and MDS. It has replaced GTB-3550 and utilizes camelid nanobody technology. GTB3650 has successfully completed pre-clinical trials and is in the good manufacturing process (GMP) stage, which is usually the last developmental milestone before progressing into phase 1 clinical trials.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GTB-3550 is the company\u2019s first TriKE\u00ae product candidate that was evaluated in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies. Phase 1 clinical trials were shown to be both safe and well-tolerated, as well as proving the molecule\u2019s clinical concept and providing a [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,20],"tags":[],"class_list":["post-169910","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-futurism"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/169910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=169910"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/169910\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=169910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=169910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=169910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}